I think we will start to see more doctors warm to the idea of trying OCTA as part of the routine clinical work-up for at-risk patients." Heidelberg Engineering's latest innovation promises to streamline workflow, enhance clinical efficiencies, and uphold superior image quality, marking a milestone in the integration of OCTA technology into routine ophthalmic practice
Real people, Real Results Join 100,000+ patients transforming their lives with GLP-1 medication Chelsea D
In the previous phase I experiment, CB-839 combined with cabozantinib demonstrated good safety and efficacy in the treatment of metastatic renal cell carcinoma (RCC) (Tannir et al., 2018
Research pipeline development through companies like Cleara Biotech provides researchers with insights into translational senolytic development while maintaining focus on research applications
Acknowledgements Mr Mike Bonar, Creative Director at Leicester Diabetes Centre, designed and created all Figures
Cum sociis natoque penatibus Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.